Previous Article | Next Article 
Journal of Virology, September 2004, p. 9560-9563, Vol. 78, No. 17
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.17.9560-9563.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Human Immunodeficiency Virus Type 1 Matrix Inhibits and Confers Cooperativity on Gag Precursor-Membrane Interactions
David Perez-Caballero, Theodora Hatziioannou, Juan Martin-Serrano, and Paul D. Bieniasz*
Aaron Diamond AIDS Research Center and the Rockefeller University, New York, New York
Received 7 February 2004/
Accepted 12 April 2004

ABSTRACT
Human immunodeficiency virus type 1 (HIV-1) Gag multimerization
and membrane binding are required for particle formation. However,
it is unclear what constitutes a minimal plasma membrane-specific
targeting signal and what role the matrix (MA) globular head
and other Gag domains play in membrane targeting. Here, we use
membrane flotation and microscopic analysis of Gag deletion
mutants to demonstrate that the HIV-1 MA globular head inhibits
a plasma membrane-specific targeting signal contained within
the six amino-terminal MA residues. MA-mediated inhibition is
relieved by concentration-dependent Gag multimerization and
imparts a high degree of cooperativity on Gag-membrane association.
This cooperativity may confer temporal and spatial regulation
on HIV-1 assembly.

TEXT
Various protein, nucleic acid, and lipid components are assembled
during retroviral particle morphogenesis, but the Gag precursor
is the only viral protein that is required for particle formation.
While most retroviruses assemble on cellular membranes, the
temporal relationship between the association of Gag with itself
and the association of Gag with membranes can vary. Human immunodeficiency
virus type 1 (HIV-1) Gag multimerization occurs primarily on
cellular membranes (
3,
23), but some degree of multimerization
may occur prior to membrane association (
1,
11), and it is controversial
whether Gag multimerization is necessary for membrane binding
(
8,
12,
19-
21). Here, we show that Gag multimerization is indeed
required for efficient membrane binding in cells, because it
overcomes an activity in the globular head of HIV-1 matrix (MA)
that inhibits membrane association. These effects confer concentration
dependence on the HIV-1 Gag-membrane interaction and are consistent
with the notion that multimerization triggers the "myristoyl
switch" (
18,
22,
25), thereby imparting a high degree of cooperativity
on HIV-1 Gag trafficking to membranes.
HIV-1 Gag binding to cellular membranes is cooperative.
Previous studies have employed membrane flotation and immunofluorescence assays to determine the degree to which HIV-1 Gag is membrane associated in cells at steady state, with varied results (3-5, 11, 16, 20). To reexamine this issue, we expressed an HIV-1 Gag-green fluorescent protein (GFP) fusion protein by using a pCR3.1-based expression vector (Invitrogen) containing codon-optimized HIV-1 Gag (6) and enhanced GFP (Clontech) sequences. A similar vector expressed unfused Gag. In 293T cells, unfused Gag and Gag-GFP were expressed at similar levels (Fig. 1A) and formed extracellular particles with similar efficiencies (data not shown). Moreover, Gag and Gag-GFP associated with cell membranes to similar degrees. This conclusion was based on membrane flotation analyses, carried out by loading lysates of transfected cells at the bottom of a 90%-65%-10% sucrose step gradient, centrifuging them at 35,000 rpm in an SW41 rotor for 18 h, and performing a Western blot analysis of gradient fractions (20) (Fig. 1B). Thus, the GFP tag should provide a good surrogate for Gag localization within cells.
At low levels of expression (100 ng of expression plasmid transfected
per 5
x 10
5 cells per well of a 24-well plate), the fraction
of Gag or Gag-GFP that associated with membranes was modest
(Fig.
1B and
2A). However, if the number of GFP tags was held
constant (by transfecting a fixed quantity [100 ng] of the Gag-GFP
expression plasmid) and the total level of Gag was varied (by
cotransfecting 900 ng of a control vector or a Gag expression
plasmid), the fraction of Gag that was membrane associated varied
dramatically (Fig.
2A). Membrane flotation assays and deconvolution
microscopy, performed as previously described (
10,
20), showed
that Gag was largely diffuse and cytoplasmic at low expression
levels but almost entirely associated with the plasma membrane
at high expression levels (Fig.
2A). Similarly, flotation analysis
revealed that unfused Gag was almost entirely associated with
cell membranes at high, but not at low, expression levels (Fig.
2B). Thus, HIV-1 Gag trafficking to the membranes is cooperative.
The globular head of MA inhibits and induces cooperativity in Gag-membrane interactions.
To determine which features of Gag were responsible for cooperative
membrane binding, we first focused on the MA globular head because
point mutations in this domain can enhance membrane binding
(
5,
13,
16). Moreover, large deletions in, or the complete removal
of, MA are compatible with HIV-1 assembly and replication (
7,
17). A fusion protein, termed Gag

GH-GFP, containing a deletion
of Gag residues 7 through 110, which encode the MA globular
head, was almost completely membrane bound, even at low Gag
expression levels (Fig.
2C). Thus, removal of the HIV-1 MA globular
head relieves a barrier to membrane association at low Gag expression
levels (compare Fig.
2A and C). Furthermore, Gag

GH-GFP localized
primarily to the plasma membrane, indicating that the MA globular
head is dispensable for specific Gag targeting. While the levels
of association of Gag

GH-GFP with membrane were not quantitatively
different under conditions of high Gag coexpression, the more
punctate distribution of Gag

GH-GFP was converted to a uniform
Gag-GFP-like membrane distribution by coexpression with excess
unfused Gag protein, suggesting that the two proteins formed
heteromultimers. Despite the differential distribution, the
deletion in the Gag

GH Gag protein was compatible with infectious
virion production in the absence of the HIV-1 gp41 cytoplasmic
tail. Indeed, a proviral plasmid carrying a GFP reporter gene
in place of Nef and the Gag

GH Gag protein generated 9.8
x 10
5 ± 2.1
x 10
5 infectious units/ml upon transfection of
293T cells, while an otherwise identical proviral plasmid encoding
an intact Gag protein generated 3.1
x 10
6 ± 0.1
x 10
6 infectious units/ml. A similar lack of requirement of the MA
globular head in spreading HIV-1 replication has been previously
reported by using similar proviral plasmid-based constructs
(
17).
A 6-residue myristoylated peptide sequence at the amino terminus of HIV-1 Gag is a specific plasma membrane targeting signal.
Previously, sequences within the globular head of HIV-1 MA, including basic residues within MA residues 15 to 31, have been reported to be important for targeting Gag specifically to the plasma membrane (2, 14, 15, 24). However, because Gag proteins entirely lacking the MA globular head appeared to target the plasma membrane (Fig. 2C), we examined which HIV Gag sequences were responsible for this specificity. We first fused a 6-residue sequence from the amino terminus of MA (MGARAS) that can support myristoylation and HIV-1 particle formation (7) directly to GFP. Biochemical and microscopic assays showed that these residues were fully sufficient to direct GFP specifically to the plasma membrane and that they did so more efficiently than did the intact HIV-1 Gag protein (Fig. 3A).
HIV-1 Gag multimerization is required to overcome the inhibitory effect of the MA globular head on plasma membrane binding.
Previously, studies that investigated the requirement for HIV-1
Gag multimerization in membrane association have reached opposing
conclusions (
12,
19). Based on the fact that HIV-1 Gag contains
a fully functional plasma membrane targeting signal (Fig.
2C and
3A), whose activity was dependent on the concentration of
Gag only when the MA globular head was present (Fig.
2A), we
reasoned that multimerization might be required for efficient
membrane binding in this context. Consistent with this idea,
a truncated Gag-GFP, termed MACA-GFP, which lacked the C-terminal
Gag sequences bound to membrane with about the same efficiency
as intact Gag at low concentrations (Fig.
3B). However, unlike
that of wild-type Gag-GFP, MACA-GFP membrane binding could not
be enhanced by an increased Gag concentration (Fig.
3B), because
MACA-GFP lacks sequences necessary for Gag multimerization,
as assessed by a previously described glutathione
S-transferase
(GST)-fusion protein coprecipitation assay (
9) (Fig.
3C).
Conclusions.
There are at least two ways in which Gag multimerization may induce membrane binding. Multimerization of low-affinity membrane-binding moieties may increase the overall membrane-binding affinity of the complex. Alternatively, multimerization may induce an increase in the intrinsic membrane-binding affinity of each Gag molecule. Clearly, each Gag monomer contains a signal that is fully sufficient to direct a heterologous protein to the plasma membrane (Fig. 3A). However, the MA globular head partly masks the activity of this signal, particularly at low concentrations of Gag (Fig. 2). This inhibitory property is relieved at high Gag concentrations, but only if Gag is able to multimerize (Fig. 2A, 3B, and 3C). While this paper was in preparation, the structures of myristoylated MA in monomeric and trimeric forms were solved (22), and they confirm the previously proposed notion that MA can exist in two conformations, distinguished by the degree of myristate exposure (25). Moreover, MA trimerization was correlated with the "myristate-exposed" conformation (22). Thus, it seems likely that at low concentrations in the cell cytoplasm, Gag is primarily monomeric, with myristate being concealed by the MA globular head, and is therefore largely cytoplasmic. As the Gag concentration is increased, a greater fraction is driven into multimeric forms, resulting in myristate exposure and efficient membrane binding. Such a mechanism might be exploited by HIV-1 to confine Gag-membrane binding and virus assembly in infected cells to a short "burst" and/or to specific cellular locations where high levels of Gag expression are reached.

ACKNOWLEDGMENTS
We thank Kyriacos Mitrophanous for the codon-optimized HIV-1
Gag gene.
This work was supported by a grant from the NIH (RO1AI50111). T.H. is the recipient of an AmFAR Scholar Award. P.D.B. is an Elizabeth Glaser Scientist of the Elizabeth Glaser Pediatric AIDS Foundation.

FOOTNOTES
* Corresponding author. Mailing address: Aaron Diamond AIDS Research Center, 455 First Ave., New York, NY 10016. Phone: (212) 448-5070. Fax: (212) 725-1126. E-mail:
pbienias{at}adarc.org.


REFERENCES
1 - Burniston, M. T., A. Cimarelli, J. Colgan, S. P. Curtis, and J. Luban. 1999. Human immunodeficiency virus type 1 Gag polyprotein multimerization requires the nucleocapsid domain and RNA and is promoted by the capsid-dimer interface and the basic region of matrix protein. J. Virol. 73:8527-8540.[Abstract/Free Full Text]
2 - Freed, E. O., J. M. Orenstein, A. J. Buckler-White, and M. A. Martin. 1994. Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J. Virol. 68:5311-5320.[Abstract/Free Full Text]
3 - Hermida-Matsumoto, L., and M. D. Resh. 2000. Localization of human immunodeficiency virus type 1 Gag and Env at the plasma membrane by confocal imaging. J. Virol. 74:8670-8679.[Abstract/Free Full Text]
4 - Khorchid, A., R. Halwani, M. A. Wainberg, and L. Kleiman. 2002. Role of RNA in facilitating Gag/Gag-Pol interaction. J. Virol. 76:4131-4137.[Abstract/Free Full Text]
5 - Kiernan, R. E., A. Ono, and E. O. Freed. 1999. Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity. J. Virol. 73:4728-4737.[Abstract/Free Full Text]
6 - Kotsopoulou, E., V. N. Kim, A. J. Kingsman, S. M. Kingsman, and K. A. Mitrophanous. 2000. A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J. Virol. 74:4839-4852.[Abstract/Free Full Text]
7 - Lee, P. P., and M. L. Linial. 1994. Efficient particle formation can occur if the matrix domain of human immunodeficiency virus type 1 Gag is substituted by a myristylation signal. J. Virol. 68:6644-6654.[Abstract/Free Full Text]
8 - Lindwasser, O. W., and M. D. Resh. 2001. Multimerization of human immunodeficiency virus type 1 Gag promotes its localization to barges, raft-like membrane microdomains. J. Virol. 75:7913-7924.[Abstract/Free Full Text]
9 - Martin-Serrano, J., A. Yarovoy, D. Perez-Caballero, and P. D. Bieniasz. 2003. Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins. Proc. Natl. Acad. Sci. USA 100:12414-12419.[Abstract/Free Full Text]
10 - Martin-Serrano, J., T. Zang, and P. D. Bieniasz. 2003. Role of ESCRT-I in retroviral budding. J. Virol. 77:4794-4804.[Abstract/Free Full Text]
11 - Morikawa, Y., D. J. Hockley, M. V. Nermut, and I. M. Jones. 2000. Roles of matrix, p2, and N-terminal myristoylation in human immunodeficiency virus type 1 Gag assembly. J. Virol. 74:16-23.[Abstract/Free Full Text]
12 - Ono, A., D. Demirov, and E. O. Freed. 2000. Relationship between human immunodeficiency virus type 1 Gag multimerization and membrane binding. J. Virol. 74:5142-5150.[Abstract/Free Full Text]
13 - Ono, A., and E. O. Freed. 1999. Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus. J. Virol. 73:4136-4144.[Abstract/Free Full Text]
14 - Ono, A., and E. O. Freed. 2004. Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. J. Virol. 78:1552-1563.[Abstract/Free Full Text]
15 - Ono, A., J. M. Orenstein, and E. O. Freed. 2000. Role of the Gag matrix domain in targeting human immunodeficiency virus type 1 assembly. J. Virol. 74:2855-2866.[Abstract/Free Full Text]
16 - Paillart, J.-C., and H. G. Göttlinger. 1999. Opposing effects of human immunodeficiency virus type 1 matrix mutations support a myristyl switch model of Gag membrane targeting. J. Virol. 73:2604-2612.[Abstract/Free Full Text]
17 - Reil, H., A. A. Bukovsky, H. R. Gelderblom, and H. G. Gottlinger. 1998. Efficient HIV-1 replication can occur in the absence of the viral matrix protein. EMBO J. 17:2699-2708.[CrossRef][Medline]
18 - Resh, M. D. 2004. A myristoyl switch regulates membrane binding of HIV-1 Gag. Proc. Natl. Acad. Sci. USA 101:417-418.[Free Full Text]
19 - Sandefur, S., V. Varthakavi, and P. Spearman. 1998. The I domain is required for efficient plasma membrane binding of human immunodeficiency virus type 1 Pr55Gag. J. Virol. 72:2723-2732.[Abstract/Free Full Text]
20 - Spearman, P., R. Horton, L. Ratner, and I. Kuli-Zade. 1997. Membrane binding of human immunodeficiency virus type 1 matrix protein in vivo supports a conformational myristyl switch mechanism. J. Virol. 71:6582-6592.[Abstract]
21 - Spearman, P., J.-J. Wang, N. Vander Heyden, and L. Ratner. 1994. Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly. J. Virol. 68:3232-3242.[Abstract/Free Full Text]
22 - Tang, C., E. Loeliger, P. Luncsford, I. Kinde, D. Beckett, and M. F. Summers. 2004. Entropic switch regulates myristate exposure in the HIV-1 matrix protein. Proc. Natl. Acad. Sci. USA 101:517-522.[Abstract/Free Full Text]
23 - Tritel, M., and M. D. Resh. 2000. Kinetic analysis of human immunodeficiency virus type 1 assembly reveals the presence of sequential intermediates. J. Virol. 74:5845-5855.[Abstract/Free Full Text]
24 - Zhou, W., L. J. Parent, J. W. Wills, and M. D. Resh. 1994. Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J. Virol. 68:2556-2569.[Abstract/Free Full Text]
25 - Zhou, W., and M. D. Resh. 1996. Differential membrane binding of the human immunodeficiency virus type 1 matrix protein. J. Virol. 70:8540-8548.[Abstract]
Journal of Virology, September 2004, p. 9560-9563, Vol. 78, No. 17
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.17.9560-9563.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Jouvenet, N., Simon, S. M., Bieniasz, P. D.
(2009). Imaging the interaction of HIV-1 genomes and Gag during assembly of individual viral particles. Proc. Natl. Acad. Sci. USA
106: 19114-19119
[Abstract]
[Full Text]
-
Sherer, N. M., Swanson, C. M., Papaioannou, S., Malim, M. H.
(2009). Matrix Mediates the Functional Link between Human Immunodeficiency Virus Type 1 RNA Nuclear Export Elements and the Assembly Competency of Gag in Murine Cells. J. Virol.
83: 8525-8535
[Abstract]
[Full Text]
-
Molle, D., Segura-Morales, C., Camus, G., Berlioz-Torrent, C., Kjems, J., Basyuk, E., Bertrand, E.
(2009). Endosomal Trafficking of HIV-1 Gag and Genomic RNAs Regulates Viral Egress. J. Biol. Chem.
284: 19727-19743
[Abstract]
[Full Text]
-
Hogue, I. B., Hoppe, A., Ono, A.
(2009). Quantitative Fluorescence Resonance Energy Transfer Microscopy Analysis of the Human Immunodeficiency Virus Type 1 Gag-Gag Interaction: Relative Contributions of the CA and NC Domains and Membrane Binding. J. Virol.
83: 7322-7336
[Abstract]
[Full Text]
-
Popov, S., Popova, E., Inoue, M., Gottlinger, H. G.
(2009). Divergent Bro1 Domains Share the Capacity To Bind Human Immunodeficiency Virus Type 1 Nucleocapsid and To Enhance Virus-Like Particle Production. J. Virol.
83: 7185-7193
[Abstract]
[Full Text]
-
Jouvenet, N., Neil, S. J. D., Zhadina, M., Zang, T., Kratovac, Z., Lee, Y., McNatt, M., Hatziioannou, T., Bieniasz, P. D.
(2009). Broad-Spectrum Inhibition of Retroviral and Filoviral Particle Release by Tetherin. J. Virol.
83: 1837-1844
[Abstract]
[Full Text]
-
Chukkapalli, V., Hogue, I. B., Boyko, V., Hu, W.-S., Ono, A.
(2008). Interaction between the Human Immunodeficiency Virus Type 1 Gag Matrix Domain and Phosphatidylinositol-(4,5)-Bisphosphate Is Essential for Efficient Gag Membrane Binding. J. Virol.
82: 2405-2417
[Abstract]
[Full Text]
-
Popov, S., Popova, E., Inoue, M., Gottlinger, H. G.
(2008). Human Immunodeficiency Virus Type 1 Gag Engages the Bro1 Domain of ALIX/AIP1 through the Nucleocapsid. J. Virol.
82: 1389-1398
[Abstract]
[Full Text]
-
Hubner, W., Chen, P., Portillo, A. D., Liu, Y., Gordon, R. E., Chen, B. K.
(2007). Sequence of Human Immunodeficiency Virus Type 1 (HIV-1) Gag Localization and Oligomerization Monitored with Live Confocal Imaging of a Replication-Competent, Fluorescently Tagged HIV-1. J. Virol.
81: 12596-12607
[Abstract]
[Full Text]
-
Stansell, E., Apkarian, R., Haubova, S., Diehl, W. E., Tytler, E. M., Hunter, E.
(2007). Basic Residues in the Mason-Pfizer Monkey Virus Gag Matrix Domain Regulate Intracellular Trafficking and Capsid-Membrane Interactions. J. Virol.
81: 8977-8988
[Abstract]
[Full Text]
-
Jager, S., Gottwein, E., Krausslich, H.-G.
(2007). Ubiquitination of Human Immunodeficiency Virus Type 1 Gag Is Highly Dependent on Gag Membrane Association. J. Virol.
81: 9193-9201
[Abstract]
[Full Text]
-
Dalton, A. K., Ako-Adjei, D., Murray, P. S., Murray, D., Vogt, V. M.
(2007). Electrostatic Interactions Drive Membrane Association of the Human Immunodeficiency Virus Type 1 Gag MA Domain. J. Virol.
81: 6434-6445
[Abstract]
[Full Text]
-
Doehle, B. P., Bogerd, H. P., Wiegand, H. L., Jouvenet, N., Bieniasz, P. D., Hunter, E., Cullen, B. R.
(2006). The Betaretrovirus Mason-Pfizer Monkey Virus Selectively Excludes Simian APOBEC3G from Virion Particles. J. Virol.
80: 12102-12108
[Abstract]
[Full Text]
-
Gomez, C. Y., Hope, T. J.
(2006). Mobility of Human Immunodeficiency Virus Type 1 Pr55Gag in Living Cells.. J. Virol.
80: 8796-8806
[Abstract]
[Full Text]
-
Coskun, A. K., van Maanen, M., Nguyen, V., Sutton, R. E.
(2006). Human chromosome 2 carries a gene required for production of infectious human immunodeficiency virus type 1.. J. Virol.
80: 3406-3415
[Abstract]
[Full Text]
-
Ryzhova, E. V., Vos, R. M., Albright, A. V., Harrist, A. V., Harvey, T., Gonzalez-Scarano, F.
(2006). Annexin 2: a Novel Human Immunodeficiency Virus Type 1 Gag Binding Protein Involved in Replication in Monocyte-Derived Macrophages. J. Virol.
80: 2694-2704
[Abstract]
[Full Text]
-
Hatziioannou, T., Martin-Serrano, J., Zang, T., Bieniasz, P. D.
(2005). Matrix-Induced Inhibition of Membrane Binding Contributes to Human Immunodeficiency Virus Type 1 Particle Assembly Defects in Murine Cells. J. Virol.
79: 15586-15589
[Abstract]
[Full Text]
-
Ono, A., Waheed, A. A., Joshi, A., Freed, E. O.
(2005). Association of Human Immunodeficiency Virus Type 1 Gag with Membrane Does Not Require Highly Basic Sequences in the Nucleocapsid: Use of a Novel Gag Multimerization Assay. J. Virol.
79: 14131-14140
[Abstract]
[Full Text]
-
Dalton, A. K., Murray, P. S., Murray, D., Vogt, V. M.
(2005). Biochemical Characterization of Rous Sarcoma Virus MA Protein Interaction with Membranes. J. Virol.
79: 6227-6238
[Abstract]
[Full Text]